Education
About Us
Working with TipRanks
Follow Us
Medicus Pharma Ltd (MDCX)
NASDAQ:MDCX
MDCX Stock Chart & Stats
$1.46
-$0.29(-9.70%)
At close: 4:00 PM EST
$1.46
-$0.29(-9.70%)
Day’s Range― - ―
52-Week Range$0.92 - $8.94
Previous CloseN/A
Volume5.92K
Average Volume (3M)529.69K
Market Cap
$17.32M
Enterprise Value$8.32M
Total Cash (Recent Filing)$8.66M
Total Debt (Recent Filing)$236.26K
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Mar 30, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding25,549,982
10 Day Avg. Volume657,308
30 Day Avg. Volume529,692
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)7.46
Price to Sales (P/S)0.00
P/FCF Ratio-2.28
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.29
Forecast
1Y Price Target
$12.00Price Target Upside721.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.55
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI-enabled Development CollaborationA one-year, milestone-based collaboration with Reliant AI provides a capital-efficient pathway to advance AI-assisted development of Teverelix and may improve trial design and data analysis.
Clinical Trial ReadoutCompletion of enrollment in the mid-stage basal cell carcinoma trial sets up a top-line data readout in the first quarter 2026, which could trigger a valuation re-rating if results confirm efficacy.
Licensing And Royalty StructureA license amendment materially reduced the royalty burden while preserving global rights and intellectual property, enhancing attractiveness for future licensing or partnering discussions.
Bears Say
Durability Of ResponsePrior mid-stage results showed strong initial responses but durability at the evaluated dose was suboptimal, creating a development risk that must be addressed in future trials.
Regulatory And Partnering UncertaintyDurability concerns introduce uncertainty with regulators and potential partners, which could weaken commercial prospects and slow progress toward licensing or collaboration agreements.
Trial Timeline And CostSuboptimal durability at the tested dose could necessitate additional dosing studies or trial redesign, extending clinical timelines and increasing development costs.
Medicus Pharma Ltd News
MDCX FAQ
What was Medicus Pharma Ltd’s price range in the past 12 months?
Medicus Pharma Ltd lowest stock price was $0.92 and its highest was $8.94 in the past 12 months.
What is Medicus Pharma Ltd’s market cap?
Medicus Pharma Ltd’s market cap is $17.32M.
When is Medicus Pharma Ltd’s upcoming earnings report date?
Medicus Pharma Ltd’s upcoming earnings report date is Mar 30, 2026 which is in 23 days.
How were Medicus Pharma Ltd’s earnings last quarter?
Medicus Pharma Ltd released its earnings results on Nov 21, 2025. The company reported -$1.12 earnings per share for the quarter, missing the consensus estimate of -$0.945 by -$0.175.
Is Medicus Pharma Ltd overvalued?
According to Wall Street analysts Medicus Pharma Ltd’s price is currently Undervalued.
Does Medicus Pharma Ltd pay dividends?
Medicus Pharma Ltd does not currently pay dividends.
What is Medicus Pharma Ltd’s EPS estimate?
Medicus Pharma Ltd’s EPS estimate is -0.07.
How many shares outstanding does Medicus Pharma Ltd have?
Medicus Pharma Ltd has 25,549,982 shares outstanding.
What happened to Medicus Pharma Ltd’s price movement after its last earnings report?
Medicus Pharma Ltd reported an EPS of -$1.12 in its last earnings report, missing expectations of -$0.945. Following the earnings report the stock price went up 4.412%.
Which hedge fund is a major shareholder of Medicus Pharma Ltd?
Currently, no hedge funds are holding shares in MDCX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medicus Pharma Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (721.92% Upside)
$12.00 (721.92% Upside)
Blogger Sentiment
Bullish
MDCX Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.92%
12-Months-Change
Fundamentals
Return on Equity
-1606.33%
Trailing 12-Months
Asset Growth
25.35%
Trailing 12-Months
Company Description
Medicus Pharma Ltd
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.
MDCX Stock 12 Month Forecast
Average Price Target
$12.00
▲(721.92% Upside)
Technical Analysis
Ovid Therapeutics
―
Jasper Therapeutics
―
Cognition Therapeutics
―
Neurosense Therapeutics Ltd.
―
PepGen Inc.
―
Ownership Overview
13.79% Insiders
0.01% Mutual Funds
6.48% Other Institutional Investors
79.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---